132 related articles for article (PubMed ID: 25355591)
1. Neuropeptide Y1 and Y5 Receptor Antagonists as Potential Anti-Obesity Drugs. Current Status.
Moreno-Herrera A; García A; Palos I; Rivera G
Mini Rev Med Chem; 2014 Oct; ():. PubMed ID: 25355591
[TBL] [Abstract][Full Text] [Related]
2. NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs.
MacNeil DJ
Curr Top Med Chem; 2007; 7(17):1721-33. PubMed ID: 17979781
[TBL] [Abstract][Full Text] [Related]
3. Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice.
Kanatani A; Mashiko S; Murai N; Sugimoto N; Ito J; Fukuroda T; Fukami T; Morin N; MacNeil DJ; Van der Ploeg LH; Saga Y; Nishimura S; Ihara M
Endocrinology; 2000 Mar; 141(3):1011-6. PubMed ID: 10698177
[TBL] [Abstract][Full Text] [Related]
4. Neuropeptide Y Y5 receptor antagonists as anti-obesity drugs.
Levens NR; Della-Zuana O
Curr Opin Investig Drugs; 2003 Oct; 4(10):1198-204. PubMed ID: 14649211
[TBL] [Abstract][Full Text] [Related]
5. Energy metabolic profile of mice after chronic activation of central NPY Y1, Y2, or Y5 receptors.
Henry M; Ghibaudi L; Gao J; Hwa JJ
Obes Res; 2005 Jan; 13(1):36-47. PubMed ID: 15761161
[TBL] [Abstract][Full Text] [Related]
6. Genetic studies of neuropeptide Y and neuropeptide Y receptors Y1 and Y5 regions in morbid obesity.
Roche C; Boutin P; Dina C; Gyapay G; Basdevant A; Hager J; Guy-Grand B; Clément K; Froguel P
Diabetologia; 1997 Jun; 40(6):671-5. PubMed ID: 9222646
[TBL] [Abstract][Full Text] [Related]
7. Regionally-selective down-regulation of NPY receptor subtypes in the obese Zucker rat. Relationship to the Y5 'feeding' receptor.
Widdowson PS
Brain Res; 1997 May; 758(1-2):17-25. PubMed ID: 9203528
[TBL] [Abstract][Full Text] [Related]
8. Neuropeptide Y1 and Y5 receptors mediate the effects of neuropeptide Y on the hypothalamic-pituitary-thyroid axis.
Fekete C; Sarkar S; Rand WM; Harney JW; Emerson CH; Bianco AC; Beck-Sickinger A; Lechan RM
Endocrinology; 2002 Dec; 143(12):4513-9. PubMed ID: 12446577
[TBL] [Abstract][Full Text] [Related]
9. Novel analogues of neuropeptide Y with a preference for the Y1-receptor.
Söll RM; Dinger MC; Lundell I; Larhammer D; Beck-Sickinger AG
Eur J Biochem; 2001 May; 268(10):2828-37. PubMed ID: 11358498
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family.
Cabrele C; Beck-Sickinger AG
J Pept Sci; 2000 Mar; 6(3):97-122. PubMed ID: 10759209
[TBL] [Abstract][Full Text] [Related]
11. An insurmountable NPY Y5 receptor antagonist exhibits superior anti-obesity effects in high-fat diet-induced obese mice.
Fukasaka Y; Nambu H; Tanioka H; Obata A; Tonomura M; Okuno T; Yukioka H
Neuropeptides; 2018 Aug; 70():55-63. PubMed ID: 29801968
[TBL] [Abstract][Full Text] [Related]
12. Evidence that the inhibition of luteinizing hormone secretion exerted by central administration of neuropeptide Y (NPY) in the rat is predominantly mediated by the NPY-Y5 receptor subtype.
Raposinho PD; Broqua P; Pierroz DD; Hayward A; Dumont Y; Quirion R; Junien JL; Aubert ML
Endocrinology; 1999 Sep; 140(9):4046-55. PubMed ID: 10465275
[TBL] [Abstract][Full Text] [Related]
13. Neuropeptide Y Stimulates Proliferation and Migration of Vascular Smooth Muscle Cells from Pregnancy Hypertensive Rats via Y1 and Y5 Receptors.
Zhang P; Qi YX; Yao QP; Chen XH; Wang GL; Shen BR; Han Y; Gao LZ; Jiang ZL
PLoS One; 2015; 10(7):e0131124. PubMed ID: 26131716
[TBL] [Abstract][Full Text] [Related]
14. Neuropeptide Y induces migration, proliferation, and tube formation of endothelial cells bimodally via Y1, Y2, and Y5 receptors.
Movafagh S; Hobson JP; Spiegel S; Kleinman HK; Zukowska Z
FASEB J; 2006 Sep; 20(11):1924-6. PubMed ID: 16891622
[TBL] [Abstract][Full Text] [Related]
15. Responsiveness of obese Zucker rats to [D-Trp34]-NPY supports the targeting of Y5 receptor for obesity treatment.
Beck B; Richy S; Stricker-Krongrad A
Nutr Neurosci; 2007; 10(5-6):211-4. PubMed ID: 18284029
[TBL] [Abstract][Full Text] [Related]
16. Co-expression of neuropeptide Y Y1 and Y5 receptors results in heterodimerization and altered functional properties.
Gehlert DR; Schober DA; Morin M; Berglund MM
Biochem Pharmacol; 2007 Dec; 74(11):1652-64. PubMed ID: 17897631
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of cloned chicken neuropeptide Y receptors Y1 and Y5.
Holmberg SK; Mikko S; Boswell T; Zoorob R; Larhammar D
J Neurochem; 2002 May; 81(3):462-71. PubMed ID: 12065655
[TBL] [Abstract][Full Text] [Related]
18. Characterization of neuropeptide Y-induced feeding in mice: do Y1-Y6 receptor subtypes mediate feeding?
Iyengar S; Li DL; Simmons RM
J Pharmacol Exp Ther; 1999 May; 289(2):1031-40. PubMed ID: 10215684
[TBL] [Abstract][Full Text] [Related]
19. Functional interaction between neuropeptide Y receptors and modulation of calcium channels in the rat hippocampus.
Silva AP; Carvalho AP; Carvalho CM; Malva JO
Neuropharmacology; 2003 Feb; 44(2):282-92. PubMed ID: 12623227
[TBL] [Abstract][Full Text] [Related]
20. ICV NPY Y1 receptor agonist but not Y5 agonist induces torpor-like hypothermia in cold-acclimated Siberian hamsters.
Pelz KM; Dark J
Am J Physiol Regul Integr Comp Physiol; 2007 Jun; 292(6):R2299-311. PubMed ID: 17332160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
